中国医药(600056) - 2024 Q1 - 季度财报

Financial Performance - The net profit attributable to shareholders of the listed company decreased by 45.83% compared to the same period last year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 44.25% year-on-year[4]. - Basic and diluted earnings per share both decreased by 45.84% compared to the previous year[4]. - The net profit for Q1 2024 was approximately 202.88 million yuan, down from 320.58 million yuan in Q1 2023[10]. - The earnings per share for Q1 2024 were 0.0973 yuan, compared to 0.1797 yuan in Q1 2023[10]. - Operating revenue for the reporting period was CNY 8,774,845,924.57, a decrease of 29.97% compared to the same period last year[32]. - Net profit attributable to shareholders of the listed company was CNY 145,599,951.99, down 45.83% year-on-year[32]. - Basic earnings per share were CNY 0.0973, reflecting a decline of 45.84% compared to the previous year[32]. - The weighted average return on equity was 1.34%, a decrease of 1.11 percentage points year-on-year[32]. - Operating profit for Q1 2024 was CNY 275,532,249.93, compared to CNY 406,844,907.96 in Q1 2023, indicating a decline of 32.3%[41]. Cash Flow and Liquidity - The net cash outflow from operating activities decreased by 285 million yuan year-on-year[4]. - Cash and cash equivalents decreased by 31.97% due to higher payments for goods[4]. - The net cash flow from operating activities was negative at CNY -1,206,669,907.55, indicating a significant cash outflow[32]. - Net cash flow from operating activities for Q1 2024 was CNY -1,206,669,907.55, an improvement from CNY -1,491,826,630.90 in Q1 2023[43]. - The company experienced a net decrease in cash and cash equivalents of -1,044,271,520.21 RMB in Q1 2024, which is an improvement from -1,373,200,424.42 RMB in Q1 2023[60]. - The ending balance of cash and cash equivalents as of the end of Q1 2024 was 2,285,987,418.56 RMB, compared to 2,137,843,807.07 RMB at the end of Q1 2023, representing an increase of approximately 6.9%[60]. Assets and Liabilities - The total assets as of March 31, 2024, amounted to 37.43 billion yuan, slightly up from 37.41 billion yuan at the end of 2023[8]. - Short-term borrowings increased to approximately 2.89 billion yuan from 2.25 billion yuan[8]. - Total current assets amounted to CNY 28,522,113,442.54, slightly down from CNY 28,526,182,765.44 at the end of the previous period[39]. - The total liabilities decreased from CNY 23,522,286,777.98 to CNY 23,333,209,572.91, indicating a reduction in financial obligations[41]. - Long-term receivables increased by 247.55% mainly due to new installment sales[4]. - Accounts receivable increased to CNY 15,218,022,490.23 from CNY 13,838,236,879.95, indicating a rise in credit sales[39]. - Inventory decreased to CNY 5,973,394,998.92 from CNY 6,232,263,429.32, suggesting improved inventory management[39]. - Long-term equity investments were CNY 2,660,032,764.68, showing a slight increase from CNY 2,649,127,464.68[39]. - Equity attributable to shareholders of the listed company increased to CNY 11,707,509,581.86, up 1.27% from CNY 11,560,548,147.45 at the end of 2023[48]. Government Support and Investment - The company received government subsidies amounting to CNY 7,012,463.86, which positively impacted the financial results[33]. - Investment income dropped by 76.14%, primarily due to reduced returns from joint ventures[50]. - In Q1 2024, the company reported a net cash outflow from investment activities of -88,272,049.61 RMB, compared to -64,462,477.80 RMB in Q1 2023, indicating an increase in investment outflows[60]. - The total cash inflow from financing activities in Q1 2024 was 2,685,103,630.73 RMB, down from 3,007,281,481.92 RMB in Q1 2023, reflecting a decrease of approximately 10.7%[60]. - The net cash flow from financing activities improved to 237,174,487.69 RMB in Q1 2024, compared to 183,430,343.94 RMB in Q1 2023, showing an increase of about 29.3%[60]. Cost Management - Total operating costs for Q1 2024 were CNY 8,513,876,388.41, down from CNY 12,093,668,632.79 in Q1 2023, reflecting a significant reduction in sales costs[41]. - Sales expenses decreased by 34.68% due to optimized marketing strategies[50]. - The company reported a decrease in deferred tax liabilities from CNY 14,051,337.00 to CNY 11,629,632.47, reflecting improved tax management[41].